Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Deals

Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development

Fineline Cube Oct 12, 2024

Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked...

Company Drug

Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B

Fineline Cube Oct 12, 2024

Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...

Company Deals

Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries

Fineline Cube Oct 12, 2024

Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences...

Company Drug

Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market

Fineline Cube Oct 11, 2024

Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...

Company Drug

Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer

Fineline Cube Oct 11, 2024

Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...

Company Drug

Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors

Fineline Cube Oct 11, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...

Company Drug

Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma

Fineline Cube Oct 11, 2024

Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...

Company Deals

Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform

Fineline Cube Oct 11, 2024

Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience...

Company Deals

XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery

Fineline Cube Oct 11, 2024

XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known...

Company Drug

Roche’s Genentech Scores FDA Approval for Itovebi in Advanced Breast Cancer Treatment, Advancing Personalized Oncology

Fineline Cube Oct 11, 2024

Roche (SWX: ROG)’s Genentech, a leader in pharmaceutical innovation, has received approval from the US...

Company Drug

Johnson & Johnson’s Darzalex Combo Therapy Gets EMA Nod for Multiple Myeloma, Aims to Set New Standard

Fineline Cube Oct 11, 2024

Johnson & Johnson (NYSE: JNJ) has taken a significant step in expanding its oncology portfolio...

Company Drug

Jiangsu Hengrui’s SHR2554 Gets Priority Review for Lymphoma Treatment, Strengthening Global EZH2 Inhibitor Market

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is on the brink of a breakthrough in...

Company Drug

Jiangsu Hengrui Secures FDA Nod for Generic Abraxane, Strengthening Oncology Portfolio

Fineline Cube Oct 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has achieved a first in the US market...

Company Medical Device

Roche’s VENTANA CLDN18 Assay Receives EU Approval, Enhances Targeted Therapy Options for Gastric Cancer

Fineline Cube Oct 11, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) has secured CE Mark approval in the European Union for...

Company Drug

Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment

Fineline Cube Oct 11, 2024

Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and...

Company

Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand

Fineline Cube Oct 11, 2024

Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...

Legal / IP Policy / Regulatory

China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting

Fineline Cube Oct 11, 2024

The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...

Company Drug Medical Device

Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China

Fineline Cube Oct 11, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have...

Company Medical Device

Sino Medical Sciences Secures NMPA Nod for Balloon Guided Catheter to Aid Vascular Procedures

Fineline Cube Oct 10, 2024

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received marketing...

Company Deals

Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors

Fineline Cube Oct 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Posts pagination

1 … 313 314 315 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.